Symmetry Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Symmetry Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,791	Closed	-$323K	–	566
2023 Q3	$323K	Hold	2,791	–	–	0.02%	415
2023 Q2	$287K	Hold	2,791	–	–	0.02%	473
2023 Q1	$305K	Sell	2,791 -12,353	-82%	-$1.37M	0.02%	451
2022 Q4	$1.72M	Hold	15,144	–	–	0.1%	106
2022 Q3	$937K	Hold	15,144	–	–	0.06%	174
2022 Q2	$1.21M	Hold	15,144	–	–	0.08%	132
2022 Q1	$1.59M	Hold	15,144	–	–	0.1%	113
2021 Q4	$1.63M	Sell	15,144 -804	-5%	-$87.7K	0.1%	122
2021 Q3	$1.82M	Hold	15,948	–	–	0.12%	114
2021 Q2	$1.49M	Hold	15,948	–	–	0.1%	144
2021 Q1	$1.47M	Hold	15,948	–	–	0.11%	135
2020 Q4	$1.17M	Buy	15,948 +598	+4%	+$44.5K	0.09%	156
2020 Q3	$1.19M	Buy	15,350 +2,997	+24%	+$206K	0.1%	132
2020 Q2	$687K	Sell	12,353 -6,316	-34%	-$270K	0.09%	101
2020 Q1	$553K	Sell	18,669 -1,848	-9%	-$62.5K	0.12%	89
2019 Q4	$743K	Hold	20,517	–	–	0.15%	88
2019 Q3	$559K	Buy	+20,517	New	+$531K	0.12%	140

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Symmetry Partners's HZNP Position: Q4 2023 in Review

Symmetry Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,791 shares — an estimated $323K sold.

Symmetry Partners first reported a position in HZNP in Q3 2019 and held it in 17 quarters. The position peaked at $1.82M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Symmetry Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Symmetry Partners sold 2,791 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $323K.
Symmetry Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 17 quarters.
Symmetry Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.82M in Q3 2021.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Symmetry Partners's 13F filing for Q4 2023, filed 2 Jan 2024.